Will Hospira’s Epogen Biosimilar Follow Sandoz’s Filgrastim Playbook?
This article was originally published in The Pink Sheet Daily
Executive Summary
Hospira’s 351(k) application includes two comparative safety and efficacy studies and two open-label long-term safety studies for epoetin biosimilar.